Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

We retain our Outperform recommendation on Hospira, Inc. (HSP - Analyst Report) following the higher-than-expected earnings reported by the company in the second quarter of 2013. The positive surprise delivered by this Zacks Rank #2 (Buy) company was its fourth consecutive earnings beat. The average beat is 8.08%. The long-term expected earnings growth rate for this stock is 7.94%.

Why the Reiteration?

On Jul 31, 2013, Hospira reported second quarter 2013 adjusted earnings of $0.55 per share, surpassing the Zacks Consensus Estimate and the year-ago earnings of $0.51. Results during the quarter were aided by lower costs.

The Specialty Injectable Pharmaceuticals segment, the biggest contributor to Hospira’s top line, performed well in the second quarter of 2013 with segmental sales climbing 7.1% (up 7.4% at constant currency) to $689.8 million. Drugs such as Precedex (a sedative) performed well during the quarter. A factor favoring the segment is the promising pipeline, which contains many injectables going off-patent in the next few years. Continued strong performance of the segment will boost Hospira’s top line.

We are also encouraged by the positive opinion issued by the European Medicines Agency’s Committee for Medicinal Products for Human Use regarding the approval of Inflectra (infliximab). Inflectra is the biosimilar version of Johnson & Johnson / Merck & Co. Inc.’s (JNJ - Analyst Report)/(MRK - Analyst Report) Remicade. The biosimilars market represents huge commercial opportunity with a significant amount of biologic sales slated to lose patent protection in the coming years.

We are also impressed by Hospira’s efforts to resolve the manufacturing issues confronting it.  We still believe that the stock is undervalued at current levels with significant scope for appreciation.

Another Stock Worth Considering

Apart from Hospira, Alere Inc. (ALR - Snapshot Report) is another favorably placed stock in the medical sector. Alere, carrying a Zacks Rank #1 (Strong Buy), is worth considering.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
VERTEX ENERG VTNR 8.25 +10.59%
CLAYTON WILL CWEI 140.03 +7.27%
E*TRADE FINA ETFC 22.67 +5.44%
KNIGHTSBRIDG VLCCF 13.22 +5.42%
CANADIAN SOL CSIQ 30.70 +5.10%